21 results found
Location: Library & Publications > Newsletters > HPRA Newsletter The Irish Medicines Board (IMB) changed its name to the Health Products Regulatory Authority (HPRA) on 1 July 2014. The mission of the Health Products Regulatory Authority is 'to protect and enhance public and animal health through the regulation of medicines, medical 13k · 22 December 2023 · Members Only
Location: About Us > College News Please see the attached correspondence from Dr Colm Henry, HSE Chief Clinical Officer and the related HPRA alert. 1k · 19 January 2024 · Members Only
Location: Library & Publications > Public Health Attached, please find a copy of the HPRA Information Notice IN2020(04) in relation to COVID-19 testing in Ireland by commercial entities outside the National Testing Strategy, for your information. 922 bytes · 24 July 2020 · Members Only
Location: Library & Publications > Public Health All in-date batches of Emerade solution for injection pre-filled pens were recalled in Ireland on September 30 2019, following a number of reports on other markets of failure to activate. 2k · 9 March 2020 · Members Only
Location: Library & Publications > Public Health In line with its remit under the Health (Pricing and Supply of Medical Goods) Act 2013, the Health Products Regulatory Authority (HPRA) will include pregabalin and gabapentin-containing medicinal products on the List of Interchangeable Medicines. 690 bytes · 3 December 2019 · Members Only
Location: ICGP Website
Ballinasloe GP Training Scheme
Library Catalogue
· 1 pages
·
Ganesaratnam, Ranga Dr.
Location: Library & Publications > Public Health Dr Fiona Lyons, National Clinical Lead for Sexual Health, has highlighted concerns expressed by the HPRA about patients sourcing Pre-exposure prophylaxis (PrEP) medicines online and made recommendations for GPs. 3k · 5 September 2017 · Members Only
Location: Library & Publications > Public Health The HPRA would like to inform you that the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) have initiated a review (Article 20 Referral) of Xeljanz (tofacitinib) following evaluation of data from an ongoing clinical trial in which an increased risk of pulmonary embolism (PE) and overall mortality was observed in patients using the tofacitinib 10mg twice daily dose. 1k · 17 May 2019 · Members Only
Location: Library & Publications > Public Health The HSE and the National Cancer Control Program (NCCP) requested the College to disseminate information to members regarding Breast Implants and the risk of Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). 783 bytes · 23 September 2019 · Members Only
Location: Library & Publications > Public Health BIA-ALCL is a rare but important disease affecting individuals with breast implants. 944 bytes · 23 May 2019 · Members Only